Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Rheumatoid Arthritis, Systemic Juvenile 1Rectal Neoplasms 1Primary Myelofibrosis 1Periodic Fevers Syndrome 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Mevalonate Kinase Deficiency 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Colonic Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1Carcinoma, Ductal 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Arthritis, Juvenile 1Arthralgia 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Clonal Cytopenia of Undetermined Significance × canakinumab × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡